Andrew  Kraft  to  Cross-Over Studies
                            
                            
                                This is a "connection" page, showing publications  Andrew  Kraft  has written about  Cross-Over Studies.
                            
                            
                            
                                
                                    
                                            
    
        
        
        
            Connection Strength
            
                
            
            0.166
         
        
        
     
 
    
        
        - 
            A randomized, open-label, phase 2, multicenter trial of gemcitabine with pazopanib or gemcitabine with docetaxel in patients with advanced soft-tissue sarcoma. Cancer. 2021 03 15; 127(6):894-904.
            
            
                Score: 0.166